Introduction: Quality of life (QoL) is a broad concept that is affected in a complex way by many factors. Healthcare interventions are targeted now days to improve quality of life of affected individuals. Glaucoma is a major cause of irreversible blindness throughout the world and affects patient's quality of life in several ways. In present study, we aim to evaluate and quantify vision related quality of life in glaucoma patients in a tertiary care hospital setting.
Materials and methods: Vision related quality of life was evaluated in glaucoma patients using GQL-15 questionnaire, which compares the subjective performance of various vision related tasks in these patients. Fifty diagnosed cases of glaucoma and fifty healthy volunteers were included in the study. In both these groups, standard tests for visual function were done and both were assigned to complete the questionnaire. GQL-15 questionnaire includes 15 items divided between 4 factors pertaining to visual disability: central and near vision, peripheral vision, dark adaptation and glare, and outdoor mobility. Higher scores indicate greater difficulty in performing vision-related activities and poorer QoL.
Results: A total of 100 cases were enrolled out of which 50 were diagnosed glaucoma cases and 50 were controls. Almost three fourth of glaucoma patients, i.e., 72% were diagnosed as chronic open angle glaucoma where 24% were angle closure patients and rest 4% were normal tension glaucoma patients. The mean GQL score of glaucoma cases was 26.00 ± 10.84 and for controls it was 15.02 ± 0.14 (p value < 0.05). All subscale scores also showed a uniform rise in their value as we move from mild to severe cases thereby concluding that all visual parameters worsen with increase in severity pattern of disease.
Conclusions: As glaucoma patients have reduced vision related quality of life, so every effort should be made to preserve visual functions in these patients. Many activities that define independence and productivity in society require good vision and hence one of most devastating consequences of advancing visual impairment in glaucoma is progressive loss of independence thereby affecting patients quality of life.
Onakoya AO, Mbadugha CA, et al. Quality Of Life of Primary Open Angle Glaucoma Patients In Lagos, Nigeria: Clinical and Sociodemographic Correlates. J Glaucoma 2012 Jun–Jul;21(5):287–295. DOI: 10.1097/IJG.0b013e31820d7cfd.
Aspinall PA, Johnson ZK, et al. Evaluation of Quality of Life and Priorities of Patients with Glaucoma. Invest Ophthalmol Vis Sci 2008;49:1907–1915. DOI: 10.1167/iovs.07-0559.
Cioffi GA, Durcan JF, et al. American Academy of Ophthalmology. Basic and Clinical Science Course-Glaucoma 2011–2012;10:3–5.
Shields MB. Textbook of Glaucoma, 4th ed; 1998. pp. 1–5.
Thylefors B, Negrel AD, et al. Global data on Blindness. Bull World Health Organ 1995;73(1):115–121.
Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol 1996;80:389–393. DOI: 10.1136/bjo.80.5.389.
Jampel HD. Glaucoma Patients’ Assessment of Their Visual Function and Quality Of Life. Trans Am Ophthalmol Soc 2001;99:301–317.
Severn P, Fraser S, et al. Which quality of life score is best for glaucoma patients and why. BMC Ophthalmol 2008;8:2. DOI: 10.1186/1471-2415- 8-2.
Goldberg I, Clement CI, et al. Assessing Quality Of Life In Patients With Glaucoma Using The Glaucoma Quality Of Life-15 (GQL-15) Questionnaire. J Glaucoma 2009 Jan;18(1):6–12. DOI: 10.1097/IJG.0b013e3181752c83.
Ware JE, Gandek B. Overview of the SF-36 health survey and the international quality of life assessment project. J Clin Epidemiol 1998;51:903–912.
Bergner M, Bobbit RA, et al. The sickness impact profile development and final revision of a health status measure. Med Care 1981;19:787–805.
Steinberg EP, Tielsch JM, et al. The VF-14: Anindex of functional impairment in patients with cataract. Arch Ophthalmol 1994;112(5):630–638. DOI: 10.1001/archopht.1994.01090170074026.
Mangione CM, Lee PP, et al. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEIVFQ). Arch Ophthalmology 1998;166:1496–1504. DOI: 10.1001/archopht.116.11.1496.
Mangione CM, Lee PP, et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2001;119:1050–1058. DOI: 10.1001/archopht.119.7.1050.
Lee BL, Gutierrez P, et al. The Glaucoma Symptom Scale. Arch Ophthalmol 1998;166:861–866. DOI: 10.1001/archopht.116.7.861.
Barber BL, Strahlman ER, et al. Validation Of A Questionnaire For Comparing The Tolerability Of Ophthalmic Medication. Ophthalmology 1997;104:334–342.
Nelson P, Aspinall P, et al. Quality Of Life In Glaucoma And Its Relationship With Visual Function. J Glaucoma 2003;12:139–150.
Janz NK, Wren PA, et al. Quality Of Life In Newly Diagnosed Glaucoma Patients: The Collaborative Initial Glaucoma Treatment Study. Ophthalmology 2001;108:887–897.
Cioffi GA, Durcan FJ, et al. Basic and Clinical Science Course- Glaucoma. American Academy of Ophthalmology 2011–2012.
Béchetoille A, Arnould B, et al. Measurement of health-related quality of life with glaucoma: validation of the Glau-Quality of life 36-item questionnaire. Acta Ophthalmol 2008 Feb;86(1):71–80. DOI: 10.1111/j.1600-0420.2007.00999.x.
Geigle R, Jones SB. Outcomes measurement: a report from the front. Inquiry 1990;27:7–13.
Parrish RK, Gedde SJ, et al. Visual function and quality of life among patients with glaucoma. Arch Ophthalmol 1997;115:1447–1455. DOI: 10.1001/archopht.1997.01100160617016.
McDermott W. Absence of Indicators of the Influence of its Physicians on a Society's Health; Impact of Physician Care on Society. Am J Med 1981;70:833–843. DOI: 10.1016/0002-9343(81)90540-4.
Medeiros FA, Gracitelli CPB, et al. Longitudinal changes in quality of life and rates of progressive visual field loss in glaucoma patients. Ophthalmology 2015;122:293–301. DOI: 10.1016/j.ophtha.2014.08.014.
Abe RY, Diniz-Filho A, et al. The impact of location of progressive visual field loss on longitudinal changes in quality of life of patients with glaucoma. Ophthalmology 2016;123:552–557. DOI: 10.1016/j.ophtha.2015.10.046.
Jampel HD, Friedman DS, et al. Correlation of the binocular visual field with patient assessment of vision. Invest Ophthalmol Vis Sci 2002;43:1059–1067.
Khadka J, Pesudovs K, et al. Reengineering the Glaucoma Quality of Life-15 questionnaire with Rasch analysis. Invest Ophthalmol Vis Sci 2011;52:6971–6977. DOI: 10.1167/iovs.11-7423.
Kumar S, Thakur S, et al. The impact of primary open-angle glaucoma: Comparison of vision-specific (National Eye Institute Visual Function Questionnaire-25) and disease-specific (Glaucoma Quality of Life-15 and Viswanathan 10) patient-reported outcome (PRO) instruments. Indian J Ophthalmol 2019 Jan;67(1):83–88. DOI: 10.4103/ijo.IJO_798_18.
Arora V, Bali SJ, et al. Impact of initial topical medical therapy on short-term quality of life in newly diagnosed patients with primary glaucoma. Indian J Ophthalmol 2015 Jun;63(6):511–515. DOI: 10.4103/0301-4738.162603.
Mbadugha CA, Onakoya AO, et al. A comparison of the NEIVFQ25 and GQL-15 questionnaires in Nigerian glaucoma patients. Clin Ophthalmol 2012;6:1411–1419. DOI: 10.2147/OPTH.S33592.
Gothwal VK, Reddy SP, et al. Impact of Glaucoma on Visual Functioning in Indians. Invest Ophthalmol Vis Sci 2012 Sep;53(10):6081–6092. DOI: 10.1167/iovs.12-9885.
Mills RP, Janz NK, et al. Correlation of Visual Field with Quality Of Life Measures at Diagnosis in the Collaborative Initial Glaucoma Treatment Study (CIGTS). J Glaucoma 2001 Nov;10:192–198.
Wang Y, Zhao Y, et al. Resilience Mediates the Relationship Between Social Support and Quality of Life in Patients With Primary Glaucoma. Front Psychiatry 2019;10:22. DOI: 10.3389/fpsyt.2019.00022.
Dada T, Mittal D, et al. Mindfulness Meditation Reduces Intraocular Pressure, Lowers Stress Biomarkers and Modulates Gene Expression in Glaucoma: A Randomized Controlled Trial. J Glaucoma 2018 Dec;27(12):1061–1067. DOI: 10.1097/IJG.000000000000 1088.
Gagrani M, Faiq MA, et al. Meditation enhances brain oxygenation, upregulates BDNF and improves quality of life in patients with primary open angle glaucoma: A randomized controlled trial. Restor Neurol Neurosci 2018;36(6):741–753. DOI: 10.3233/RNN-180857.